Gabrielle Zhou's questions to SBOT leadership • Q2 2016
Question
Gabrielle Zhou of Maxim Group inquired about the commercial production forecast for KLH for the remainder of the year and beyond, as well as the progress of key partners like Neovacs in their use of KLH for active immunotherapies.
Answer
President and CEO Frank Oakes explained that while he could not offer specific forecasts, Stellar expects continued strong growth in demand for KLH, with production anticipated to move from gram to kilogram quantities in future years. Regarding partners, he pointed to Neovacs' public announcements about advancing their lupus trial into the United States as a positive indicator of progress.